Fifth Third Bancorp Acquires 11,994 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Fifth Third Bancorp raised its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 156.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,654 shares of the company’s stock after buying an additional 11,994 shares during the quarter. Fifth Third Bancorp’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $562,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Park Avenue Securities LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $256,000. Millennium Management LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 50.0% in the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after buying an additional 361,364 shares during the period. AQR Capital Management LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 14.2% in the 1st quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock valued at $356,000 after buying an additional 1,777 shares during the period. Advisors Asset Management Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 243.3% in the 1st quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company’s stock valued at $195,000 after buying an additional 5,540 shares during the period. Finally, Vident Advisory LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 131.8% in the 1st quarter. Vident Advisory LLC now owns 54,274 shares of the company’s stock valued at $1,351,000 after buying an additional 30,864 shares during the period. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE:FMS opened at $25.76 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $18.94 and a 12 month high of $30.46. The company’s 50-day moving average price is $25.22 and its two-hundred day moving average price is $26.09. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The firm had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. On average, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Finally, UBS Group reaffirmed a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Reduce” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.